The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The industry rank for Valiant Laboratories's 14-Day RSI or its related term are showing as below:
NSE:VALIANTLAB's 14-Day RSI is ranked better than 87.31% of 1048
companies
in the Drug Manufacturers industry
Industry Median: 50.745
vs NSE:VALIANTLAB: 34.76
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Valiant Laboratories 14-Day RSI Related Terms
NSE:VALIANTLAB vs ZTS, UTHR: 14-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valiant Laboratories 14-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Valiant Laboratories's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valiant Laboratories (NSE:VALIANTLAB) has a 14-Day RSI of 34.76 as of Jul. 06, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Valiant Laboratories and its competitors. According to the industry distribution chart, Valiant Laboratories ranks #133 out of 1048 companies in the Drug Manufacturers industry, placing it in the top 12.7%.
Is Valiant Laboratories' 14-Day RSI too high?
Valiant Laboratories' current 14-Day RSI is 34.76. The Drug Manufacturers industry median 14-Day RSI is 50.75. Valiant Laboratories' value of 34.76 is 31.5% below this industry median. Based on the distribution chart, Valiant Laboratories ranks #133 out of 1048 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Valiant Laboratories has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valiant Laboratories' 14-Day RSI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Valiant Laboratories ranks #133 out of 1048 companies for 14-Day RSI. This places Valiant Laboratories in the top 13% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 50.75. Valiant Laboratories' value of 34.76 is 31.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Drug Manufacturers company?
The median 14-Day RSI among Drug Manufacturers companies is 50.75, based on 1,048 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valiant Laboratories's current 14-Day RSI of 34.76 is 31.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Valiant Laboratories and its competitors. For the Drug Manufacturers industry, the median 14-Day RSI is 50.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valiant Laboratories's current 14-Day RSI is 34.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valiant Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Valiant Laboratories (NSE:VALIANTLAB) is currently considered Possible Value Trap. The stock's GF Value™ is ₹102.67, compared to a current price of ₹65.01 — trading 36.7% below its estimated fair value. The current 14-Day RSI is 34.76 and 31.5% below the Drug Manufacturers industry median of 50.75. Valiant Laboratories' overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Valiant Laboratories (NSE:VALIANTLAB), the current 14-Day RSI is 34.76 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued.
The current stock price of ₹65.01 is trading 36.7% below its estimated GF Value™ of ₹102.67.
GuruFocus considers Valiant Laboratories to be Possible Value Trap.
Key valuation signals for NSE:VALIANTLAB:
14-Day RSI: 34.76
GF Value™: ₹102.67 vs. price of ₹65.01 (36.7% below fair value)
Industry Position: 31.5% below the Drug Manufacturers median (#133 of 1048)
No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
58GF Score
Get the complete analysis for NSE:VALIANTLAB
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VALIANTLAB has been successfully added to your 